GLP-1 medicine in the news
GLP-1 medications have been studied in large clinical trials and covered across major media and medical journals. Here is a look at the moment, and where the evidence stands.
Free 60-second assessment. No payment to start.
GLP-1 medicine has been reported on by
Science · 2023
Science, one of the world's leading peer-reviewed journals, named GLP-1 medications for obesity its 2023 Breakthrough of the Year, citing evidence that the class blunts obesity-associated health problems beyond weight alone.
Science, Breakthrough of the Year 2023 ↗The research
In the STEP 1 trial, adults on weekly semaglutide lost 14.9% of their body weight on average over 68 weeks. In SURMOUNT-1, adults on weekly tirzepatide lost between 16% and 22.5%. Both were published in the New England Journal of Medicine.
See the research breakdown→The cultural moment
From medical journals to national newspapers, GLP-1 medicine became one of the most widely covered health stories of the decade, shifting the conversation about weight from willpower toward biology and hormones.
A licensed US provider reviews every request. You only pay if you are approved.
Start my free assessment->